Cross‐sectional investigation of drug‐related problems among adults in a medical center outpatient clinic: application of virtual medicine records in the cloud

Wang, Hue-Yu; Yeh, Ming–Kung; Ho, Chung‐Han; Hu, Ming‐Kuan; Huang, Yaw‐Bin

doi:10.1002/pds.4117

Cited by 3 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DRPs for drug indications had the highest proportion of prescriptions' DRPs (53.5%). This result was similar to Hue Yu Wang et al ( 2017) study at a medical center outpatient clinic in Taiwan (50.2%) 7 but higher than in prescribing for pediatric outpatients in Vietnam (35.6%) 14 .…”

Section: Drps For Drug Indicationssupporting

confidence: 89%

See 1 more Smart Citation

Pharmacist-led interventions to reduce drug-related problems in prescribing for Vietnamese outpatients

Nguyen¹,

Nguyễn²,

Pham³

et al. 2022

Pharm Sci Asia

View full text Add to dashboard Cite

Inappropriate prescribing reduces the quality of treatment and leads to a waste of resources 1 . The World Health Organization estimates that more than half of all drugs are prescribed, dispensed, or sold inappropriately, and that half of all patients do not take them correctly 2 . Drug-related problems can increase the risk of side effects, drug interactions, antimicrobial resistance, increase costs for treatment (in terms of both direct medication costs and indirect medication costs), and pressure the insurance budget society. According to the studies, about 50% to 80% of drug-related problems may be preventable 3 . In particular, clinical pharmacists help identify, treat and have a crucial role in preventing drug-related problems through specific interventions. The pharmacist's contribution to improving the quality of medication use and patient safety can be assessed directly or indirectly by determining the number of drug-related problems being managed/prevented or by cost-effective treatment 4 .All over the world, many studies are showing the critical role of pharmacists in identifying and managing drug-related problems in prescribing [5][6] . In Sweden, pharmacists' recommendations on DRPs might positively influence physicians' prescribing quality and contribute to better and safer drug therapy for patients 5 . In addition, Japanese pharmacists also had an essential role in providing medication safety, with potential cost savings 6 .

show abstract

Section: Drps For Drug Indicationssupporting

confidence: 89%

“…The single proportion formula was used to estimate the required sample size by considering the following assumptions: the proportion of DRP 50.2% 7 , a 95% confidence level, and a 2% margin of error. However, the research team collected prescriptions for 15 days from all doctors attending the clinics.…”

Section: Sample Sizementioning

confidence: 99%

Pharmacist-led interventions to reduce drug-related problems in prescribing for Vietnamese outpatients

Nguyen¹,

Nguyễn²,

Pham³

et al. 2022

Pharm Sci Asia

View full text Add to dashboard Cite

show abstract

“…Drug-related problems (DRP) affected 50% of the patients and were most frequently encountered for "Drugs for the Cardiovascular System" and caused by inappropriate duplication of the therapeutic group or active ingredient. Our data show a similar pattern of DDI and duplicate therapy distribution [17].…”

Section: Discussionsupporting

confidence: 79%

Prevalence of Drug-Drug Interactions and Duplicate Therapy in Chronic Patients in Switzerland: A Real-World Data Study

Hafizi¹,

Bauert²

2022

Preprint

View full text Add to dashboard Cite

The primary purpose of this study was to determine the prevalence of drug-drug interaction (DDI) and duplicate therapy in chronic patients in a completely random study population engaged in digital health apps. In this cross-sectional study, polypharmacy checks for 100 completely anonymous patients were analyzed for the occurrence of DDIs and duplicate therapy. Logistic regression models were used to identify factors associated with DDIs and duplicate therapy. DDIs and duplicate therapy prevalence were 34% and 33%, respectively. Chi-Square test discovered a significant association between the DDIs and duplicate therapy variables. Logistic regression models showed a strong association between the number of medications taken and higher odds of DDIs occurring in our population only. In conclusion, our study shows that polypharmacy is a determining factor for the occurrence of unwanted DDIs, and the prevalence of duplicate therapy and DDIs is around 33%, increasing an issue regarding patient safety and its burden to the healthcare system.

show abstract

“…Among available classification systems, PCNE, a hierarchical classification system according to types and causes of DRPs, as well as pharmacists' interventions, acceptances and outcomes, is widely used in DRPs description (1,2,10). In prior seven DRPs-related studies in China, four applied the PCNE classification system (11)(12)(13)(14), one used the DOCUMENT classification system (15), and the other two categorized the DRPs by researchers themselves rather than any classification system (8,16).…”

Section: Original Articlementioning

confidence: 99%

Drug-related problems among hospitalized cancer pain patients: an investigative single-arm intervention trial

Su¹,

Yan²,

Wang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: To evaluate the characteristics of drug-related problems (DRPs) in cancer pain patients, and to identify the impact of pharmacists' intervention in cancer pain associated DRPs. Methods: In this investigative, single-arm intervention study, clinical pharmacists identified DRPs in cancer pain patients and provided interventions based on medication information, direct patient-pharmacist interview, and ward rounds with multi-disciplinary team (MDT). Types and causes of DRPs, interventions, acceptance and outcome were sorted based on Pharmaceutical Care Network Europe (PCNE) DRP classification V9.0, which includes 3 primary domains for problems, 9 for causes, 5 for interventions, 3 for acceptance, and 4 for DRPs status.Results: Totally, 42 cancer pain patients were enrolled, and 47 DRPs in 33 (78.6%) patients were identified by clinical pharmacists. The major type of DRPs was treatment effectiveness (30; 63.8%) and treatment safety (17; 36.2%). For the "treatment effectiveness" category, the "effect of drug treatment not optimal" was dominant category (27/30; 90%). A total of 66 DRP causes were identified, and most of DRPs were caused by "drug selection" (27; 40.9%) and "dose selection" (16; 24.2%). Within the "drug selection" category, "no or incomplete drug treatment in spite of existing indication" was dominant category (25/27; 92.6%). According toDRPs, 159 interventions were provided by clinical pharmacists and 99.4% of interventions were accepted by prescribers or patients. Finally, 44 (93.6%) DRPs were solved. Conclusions: In cancer pain patients, insufficient pain control mainly caused by inappropriate selection and dosage of analgesics. Clinical pharmacists' interventions dramatically ameliorate these problems and bring about positive effects in cancer pain pharmacotherapy.

show abstract

Cross‐sectional investigation of drug‐related problems among adults in a medical center outpatient clinic: application of virtual medicine records in the cloud

Abstract: With VMRCS, DRPs were more easily identified whether patients received medical care in the same hospital or not. DRPs could be efficiently prevented through the use of pre-downloaded patient prescription data. Copyright © 2016 John Wiley & Sons, Ltd.

Cited by 3 publications

References 32 publications

Pharmacist-led interventions to reduce drug-related problems in prescribing for Vietnamese outpatients

Pharmacist-led interventions to reduce drug-related problems in prescribing for Vietnamese outpatients

Prevalence of Drug-Drug Interactions and Duplicate Therapy in Chronic Patients in Switzerland: A Real-World Data Study

Drug-related problems among hospitalized cancer pain patients: an investigative single-arm intervention trial

Contact Info

Product

Resources

About